How I treat monoclonal gammopathy of renal significance (MGRS)

Jean Paul Fermand, Frank Bridoux, Robert A. Kyle, Efstathios Kastritis, Brendan M. Weiss, Mark A. Cook, Mark T. Drayson, Angela Dispenzieri, Nelson Leung

Research output: Contribution to journalArticle

128 Citations (Scopus)

Abstract

Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases.

Original languageEnglish (US)
Pages (from-to)3583-3590
Number of pages8
JournalBlood
Volume122
Issue number22
DOIs
StatePublished - Nov 21 2013

Fingerprint

Paraproteinemias
Immunoglobulin Light Chains
Kidney
Clone cells
Kidney Diseases
Amyloidosis
Clone Cells
Clinical Trials
Life Support Care
Therapeutics
Multiple Myeloma
Proteins
Kidney Transplantation
Lymphoma
B-Lymphocytes
Recurrence

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Fermand, J. P., Bridoux, F., Kyle, R. A., Kastritis, E., Weiss, B. M., Cook, M. A., ... Leung, N. (2013). How I treat monoclonal gammopathy of renal significance (MGRS). Blood, 122(22), 3583-3590. https://doi.org/10.1182/blood-2013-05-495929

How I treat monoclonal gammopathy of renal significance (MGRS). / Fermand, Jean Paul; Bridoux, Frank; Kyle, Robert A.; Kastritis, Efstathios; Weiss, Brendan M.; Cook, Mark A.; Drayson, Mark T.; Dispenzieri, Angela; Leung, Nelson.

In: Blood, Vol. 122, No. 22, 21.11.2013, p. 3583-3590.

Research output: Contribution to journalArticle

Fermand, JP, Bridoux, F, Kyle, RA, Kastritis, E, Weiss, BM, Cook, MA, Drayson, MT, Dispenzieri, A & Leung, N 2013, 'How I treat monoclonal gammopathy of renal significance (MGRS)', Blood, vol. 122, no. 22, pp. 3583-3590. https://doi.org/10.1182/blood-2013-05-495929
Fermand JP, Bridoux F, Kyle RA, Kastritis E, Weiss BM, Cook MA et al. How I treat monoclonal gammopathy of renal significance (MGRS). Blood. 2013 Nov 21;122(22):3583-3590. https://doi.org/10.1182/blood-2013-05-495929
Fermand, Jean Paul ; Bridoux, Frank ; Kyle, Robert A. ; Kastritis, Efstathios ; Weiss, Brendan M. ; Cook, Mark A. ; Drayson, Mark T. ; Dispenzieri, Angela ; Leung, Nelson. / How I treat monoclonal gammopathy of renal significance (MGRS). In: Blood. 2013 ; Vol. 122, No. 22. pp. 3583-3590.
@article{fbe3697e542b4d7bb594a090a47265b5,
title = "How I treat monoclonal gammopathy of renal significance (MGRS)",
abstract = "Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases.",
author = "Fermand, {Jean Paul} and Frank Bridoux and Kyle, {Robert A.} and Efstathios Kastritis and Weiss, {Brendan M.} and Cook, {Mark A.} and Drayson, {Mark T.} and Angela Dispenzieri and Nelson Leung",
year = "2013",
month = "11",
day = "21",
doi = "10.1182/blood-2013-05-495929",
language = "English (US)",
volume = "122",
pages = "3583--3590",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "22",

}

TY - JOUR

T1 - How I treat monoclonal gammopathy of renal significance (MGRS)

AU - Fermand, Jean Paul

AU - Bridoux, Frank

AU - Kyle, Robert A.

AU - Kastritis, Efstathios

AU - Weiss, Brendan M.

AU - Cook, Mark A.

AU - Drayson, Mark T.

AU - Dispenzieri, Angela

AU - Leung, Nelson

PY - 2013/11/21

Y1 - 2013/11/21

N2 - Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases.

AB - Recently, the term monoclonal gammopathy of renal significance (MGRS) was introduced to distinguish monoclonal gammopathies that result in the development of kidney disease from those that are benign. By definition, patients with MGRS have B-cell clones that do not meet the definition of multiple myeloma or lymphoma. Nevertheless, these clones produce monoclonal proteins that are capable of injuring the kidney resulting in permanent damage. Except for immunoglobulin light chain amyloidosis with heart involvement in which death can be rapid, treatment of MGRS is often indicated more to preserve kidney function and prevent recurrence after kidney transplantation rather than the prolongation of life. Clinical trials are rare for MGRS-related kidney diseases, except in immunoglobulin light chain amyloidosis. Treatment recommendations are therefore based on the clinical data obtained from treatment of the clonal disorder in its malignant state. The establishment of these treatment recommendations is important until data can be obtained by clinical trials of MGRS-related kidney diseases.

UR - http://www.scopus.com/inward/record.url?scp=84888228292&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84888228292&partnerID=8YFLogxK

U2 - 10.1182/blood-2013-05-495929

DO - 10.1182/blood-2013-05-495929

M3 - Article

C2 - 24108460

AN - SCOPUS:84888228292

VL - 122

SP - 3583

EP - 3590

JO - Blood

JF - Blood

SN - 0006-4971

IS - 22

ER -